Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (141-150 of 205) with videos related to

Pageof 21
Sort By:
Blood|March 19, 2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phaseAndreas Hochhaus, Giuseppe Saglio, Richard A Larson, et al.
Blood Advances|January 4, 2018
<i>ASXL1</i> and <i>BIM</i> germ line variants predict response and identify CML patients with the greatest risk of imatinib failureJustine E Marum, David T Yeung, Leanne Purins, et al.
Leukemia & Lymphoma|May 22, 2014
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trialJason D Lickliter, Kerry Taylor, Jeff Szer, et al.
Blood|December 17, 2013
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibTimothy P Hughes, Giuseppe Saglio, Hagop M Kantarjian, et al.
The Lancet. Oncology|August 23, 2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialHagop M Kantarjian, Andreas Hochhaus, Giuseppe Saglio, et al.
Nature|April 15, 2008
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of IkarosCharles G Mullighan, Christopher B Miller, Ina Radtke, et al.
The New England Journal of Medicine|March 9, 2017
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaAndreas Hochhaus, Richard A Larson, François Guilhot, et al.
Blood|June 21, 2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinibTimothy P Hughes, Jeffrey H Lipton, Nelson Spector, et al.
The New England Journal of Medicine|June 8, 2010
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaGiuseppe Saglio, Dong-Wook Kim, Surapol Issaragrisil, et al.
Haematologica|February 18, 2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyTimothy P Hughes, Andreas Hochhaus, Hagop M Kantarjian, et al.
Pageof 21

Showing results (141-150 of 205) with videos related to

Sort By:
Pageof 21
Blood|March 19, 2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phaseAndreas Hochhaus, Giuseppe Saglio, Richard A Larson, et al.
Blood Advances|January 4, 2018
<i>ASXL1</i> and <i>BIM</i> germ line variants predict response and identify CML patients with the greatest risk of imatinib failureJustine E Marum, David T Yeung, Leanne Purins, et al.
Leukemia & Lymphoma|May 22, 2014
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trialJason D Lickliter, Kerry Taylor, Jeff Szer, et al.
Blood|December 17, 2013
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibTimothy P Hughes, Giuseppe Saglio, Hagop M Kantarjian, et al.
The Lancet. Oncology|August 23, 2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialHagop M Kantarjian, Andreas Hochhaus, Giuseppe Saglio, et al.
Nature|April 15, 2008
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of IkarosCharles G Mullighan, Christopher B Miller, Ina Radtke, et al.
The New England Journal of Medicine|March 9, 2017
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaAndreas Hochhaus, Richard A Larson, François Guilhot, et al.
Blood|June 21, 2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinibTimothy P Hughes, Jeffrey H Lipton, Nelson Spector, et al.
The New England Journal of Medicine|June 8, 2010
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaGiuseppe Saglio, Dong-Wook Kim, Surapol Issaragrisil, et al.
Haematologica|February 18, 2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyTimothy P Hughes, Andreas Hochhaus, Hagop M Kantarjian, et al.
Pageof 21